Pulmonary Embolism as an Adverse Drug Event of Intravenous Immunoglobulin Therapy

Katasha S. Butler; Deborah S. Zeitlin

doi:10.1345/aph.1D037L

Pulmonary Embolism as an Adverse Drug Event of Intravenous Immunoglobulin Therapy

Research output: Contribution to journal › Article › peer-review

Abstract

TO THE EDITOR: Intravenous immunoglobulin (IVIG) therapy has gained popularity for the treatment of neuromuscular diseases (i.e., myasthenia gravis, inflammatory myopathy, chronic inflammatory demyelinating polyneuropathy), although adverse events are associated with high-dose IVIG infusions. ^1,2 Common adverse reactions to IVIG therapy are anxiety, headache, fever, chills, chest pain, dyspnea, nausea, and abdominal pain. ³ More serious adverse events include anaphylaxis, hemolytic anemia, hepatitis C, and thrombosis. ³ Studies have shown documented effects of IVIG on blood rheology. It increases plasma viscosity in a dose-related response and may also activate platelets. ^2–4 High-dose IVIG therapy is approximately 24–54 g/d. ⁴

Original language	American English
Journal	Scholarship and Professional Work – COPHS
Volume	37
DOIs	https://doi.org/10.1345/aph.1D037L
State	Published - Jan 1 2003

Keywords

IVIG
adverse events
case report
evidence based practice
high dose
intravenous immunoglobulin therapy
letter to the editor

Disciplines

Medicine and Health Sciences
Pharmacy and Pharmaceutical Sciences

Access to Document

10.1345/aph.1D037LLicense: Unspecified

Pulmonary Embolism as an Adverse Drug Event of Intravenous ImmunoFinal published version, 317 KBLicense: Unspecified

Cite this

@article{492733c9d8424fbdbc6b54289f369b83,

title = "Pulmonary Embolism as an Adverse Drug Event of Intravenous Immunoglobulin Therapy",

abstract = " TO THE EDITOR: Intravenous immunoglobulin (IVIG) therapy has gained popularity for the treatment of neuromuscular diseases (i.e., myasthenia gravis, inflammatory myopathy, chronic inflammatory demyelinating polyneuropathy), although adverse events are associated with high-dose IVIG infusions. 1,2 Common adverse reactions to IVIG therapy are anxiety, headache, fever, chills, chest pain, dyspnea, nausea, and abdominal pain. 3 More serious adverse events include anaphylaxis, hemolytic anemia, hepatitis C, and thrombosis. 3 Studies have shown documented effects of IVIG on blood rheology. It increases plasma viscosity in a dose-related response and may also activate platelets. 2–4 High-dose IVIG therapy is approximately 24–54 g/d. 4 ",

keywords = "IVIG, adverse events, case report, evidence based practice, high dose, intravenous immunoglobulin therapy, letter to the editor",

author = "Butler, {Katasha S.} and Zeitlin, {Deborah S.}",

year = "2003",

month = jan,

day = "1",

doi = "10.1345/aph.1D037L",

language = "American English",

volume = "37",

journal = "Scholarship and Professional Work – COPHS",

}

TY - JOUR

T1 - Pulmonary Embolism as an Adverse Drug Event of Intravenous Immunoglobulin Therapy

AU - Butler, Katasha S.

AU - Zeitlin, Deborah S.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - TO THE EDITOR: Intravenous immunoglobulin (IVIG) therapy has gained popularity for the treatment of neuromuscular diseases (i.e., myasthenia gravis, inflammatory myopathy, chronic inflammatory demyelinating polyneuropathy), although adverse events are associated with high-dose IVIG infusions. 1,2 Common adverse reactions to IVIG therapy are anxiety, headache, fever, chills, chest pain, dyspnea, nausea, and abdominal pain. 3 More serious adverse events include anaphylaxis, hemolytic anemia, hepatitis C, and thrombosis. 3 Studies have shown documented effects of IVIG on blood rheology. It increases plasma viscosity in a dose-related response and may also activate platelets. 2–4 High-dose IVIG therapy is approximately 24–54 g/d. 4

AB - TO THE EDITOR: Intravenous immunoglobulin (IVIG) therapy has gained popularity for the treatment of neuromuscular diseases (i.e., myasthenia gravis, inflammatory myopathy, chronic inflammatory demyelinating polyneuropathy), although adverse events are associated with high-dose IVIG infusions. 1,2 Common adverse reactions to IVIG therapy are anxiety, headache, fever, chills, chest pain, dyspnea, nausea, and abdominal pain. 3 More serious adverse events include anaphylaxis, hemolytic anemia, hepatitis C, and thrombosis. 3 Studies have shown documented effects of IVIG on blood rheology. It increases plasma viscosity in a dose-related response and may also activate platelets. 2–4 High-dose IVIG therapy is approximately 24–54 g/d. 4

KW - IVIG

KW - adverse events

KW - case report

KW - evidence based practice

KW - high dose

KW - intravenous immunoglobulin therapy

KW - letter to the editor

UR - https://digitalcommons.butler.edu/cophs_papers/182

U2 - 10.1345/aph.1D037L

DO - 10.1345/aph.1D037L

M3 - Article

VL - 37

JO - Scholarship and Professional Work – COPHS

JF - Scholarship and Professional Work – COPHS

ER -

Pulmonary Embolism as an Adverse Drug Event of Intravenous Immunoglobulin Therapy

Abstract

Keywords

Disciplines

Access to Document

Other files and links

Cite this